拜耳将在2025年ESG会议上展示关于晚期化合物elinzanetant及其对更年期症状影响的研究-动脉网

Bayer to present research on late-stage compound elinzanetant and impact on menopause symptoms at ESG 2025

拜耳等信源发布 2025-03-13 15:38



可切换为仅中文







March

三月

2025

08:30 AM

早上8点30分

Europe/Amsterdam

欧洲/阿姆斯特丹

Bayer to present research on late-stage compound elinzanetant and impact on menopause symptoms at ESG 2025

拜耳将在2025年欧洲更年期学会（ESG）上展示关于晚期化合物elinzanetant及其对更年期症状影响的研究。

Not intended for U.S. and UK Media – 16th Congress of the European Society of Gynecology (ESG):

不适用于美国和英国媒体——欧洲妇科学会（ESG）第16届大会：

Summary

摘要

Poster presentations on findings from two Phase III studies with elinzanetant on the treatment of vasomotor symptoms, the impact of sleep disturbances on quality of life, as well as pooled data from several subgroup analyses / These poster presentations reinforce Bayer’s leading position and commitment to understanding and advancing women’s healthcare specifically for those who are experiencing menopause symptoms.

关于elinzanetant治疗血管舒缩症状的两项III期研究结果、睡眠障碍对生活质量的影响，以及来自多个亚组分析的汇总数据的海报展示 / 这些海报展示进一步巩固了拜耳在理解并推动女性医疗保健领域的领先地位和承诺，特别是针对那些正在经历更年期症状的女性。

Berlin, March 13, 2025

柏林，2025年3月13日

– Bayer will present additional research results from its Phase III development program with elinzanetant on treating menopause symptoms at the upcoming 16

– 拜耳将在即将到来的第16届会议上展示其关于elinzanetant治疗更年期症状的III期开发项目的更多研究成果。

Congress of the European Society of Gynecology (ESG) which takes place from March 19 – 22 in Riga, Latvia. Results include the impact of sleep disturbances on women’s health and quality of life as well as the effect of elinzanetant for the treatment of vasomotor symptoms associated with menopause and pooled data from several subgroup analyses from two Phase III studies with elinzanetant..

欧洲妇科协会（ESG）大会将于3月19日至22日在拉脱维亚里加举行。结果包括睡眠障碍对女性健康和生活质量的影响，以及elinzanetant治疗与更年期相关的血管舒缩症状的效果，还有来自两项III期研究的多个亚组分析的汇总数据。

The research to be presented demonstrates the continuous commitment of Bayer as a leader in women’s healthcare to advance science, increase awareness and education around menopause as well as to broaden therapeutic options in an area of high unmet medical need.

这项研究展示了拜耳作为女性医疗保健领域的领导者，持续致力于推动科学发展、提高对更年期的认识和教育，以及在未满足医疗需求高的领域拓宽治疗选择。

Bayer oral presentation at ESG 2025 of interest:

拜耳在2025年ESG会议上的口头报告备受关注：

Oral presentation:

口头报告：

“Associations between Vasomotor Symptoms, Sleep Disturbances, and Frequent Mood Changes in Menopausal Women: Analysis of Data from the Study of Women's Health Across the Nation”

“绝经期女性血管舒缩症状、睡眠障碍与频繁情绪变化之间的关联：基于全国女性健康研究数据的分析”

o Carina Dinkel-Keuthage

o 卡琳娜·丁克尔-科萨奇

o Friday, March 21

o 星期五，3月21日

开始

，

2025: 09:45-11:15 CET, Hall GAMMA

2025年：09:45-11:15 中欧时间，伽马大厅

Bayer additional presentations at ESG 2025 include:

拜耳在ESG 2025上的其他演讲包括：

Poster #52: “Sleep disturbance in menopausal women with vasomotor symptoms: findings from two Phase 3 studies”

海报#52：“伴有血管舒缩症状的绝经期女性睡眠障碍：两项3期研究的结果”

o Cecilia Caetano

o 塞西莉亚·凯塔诺

o Wednesday, March 19

o 星期三，3月19日

, 2025, 18:30-20:00 CET, Foyer 2

，2025年，18:30-20:00欧洲中部时间，门厅2

Poster #53: “Effect of elinzanetant for the treatment of vasomotor symptoms associated with menopause: pooled data from two Phase 3 studies”

海报#53：“Elinzanetant治疗与更年期相关的血管舒缩症状的效果：来自两项三期研究的汇总数据”

o Nick Panay

o 尼克·帕纳伊

o Wednesday, March 19

o 星期三，3月19日

, 2025, 18:30-20:00 CET, Foyer 2

，2025年，18:30-20:00 中欧时间，大厅2

Poster #55: “EMPOWER: Evaluating Menopausal symPtom treatment Options and WomEns’ pReferences”

海报 #55：“EMPOWER：评估更年期症状治疗选项与女性偏好”

o Cecilia Caetano

o 塞西莉亚·凯塔诺

o Wednesday, March 19

o 星期三，3月19日

, 2025, 18:30-20:00 CET, Foyer 2

，2025年，18:30-20:00 中欧时间，大厅2

Poster #58: “Does sleep disturbance have an impact on depression and anxiety in perimenopausal and postmenopausal women? A Europe-based survey“

海报 #58：“睡眠障碍是否对围绝经期和绝经后女性的抑郁和焦虑有影响？一项基于欧洲的调查”

o Carina Dinkel-Keuthage

凯莉娜·丁克尔-科萨奇

o Wednesday, March 19

o 星期三，3月19日

, 2025, 18:30-20:00 CET, Foyer 2

，2025年，18:30-20:00 中欧时间，门厅2

Poster #61: “Effect of elinzanetant for the treatment of vasomotor symptoms associated with menopause across BMI and smoking history subgroups: pooled data from two Phase 3 studies”

海报#61：“Elinzanetant治疗与绝经相关的血管舒缩症状在BMI和吸烟史亚组中的效果：来自两项III期研究的汇总数据”

o Rosella E Nappi

罗塞拉·E·纳皮

o Wednesday, March 19

o 星期三，3月19日

, 2025, 18:30-20:00 CET, Foyer 2

，2025年，18:30-20:00 欧洲中部时间，大厅2

Poster #62: “Effect of elinzanetant for the treatment of vasomotor symptoms associated with menopause across race and ethnicity subgroups: pooled data from two Phase 3 studies”

海报#62：“Elinzanetant治疗与更年期相关的血管舒缩症状在种族和民族亚组中的效果：来自两项III期研究的汇总数据”

o Rosella E Nappi

罗塞拉·E·纳皮

o Wednesday, March 19

o 星期三，3月19日

第

, 2025, 18:30-20:00 CET, Foyer 2

，2025年，18:30-20:00 中欧时间，大厅2

Elinzanetant 是首个双重神经激肽-1和3（NK-1,3）受体拮抗剂，目前处于晚期临床开发阶段，用于针对性治疗与更年期相关或由乳腺癌辅助内分泌治疗引起的中度至重度血管舒缩症状（VMS），每日口服一次。OASIS 1 和 2 的数据已发表在《美国医学会杂志》上。

JAMA

美国医学会杂志

)

in August 2024. Detailed results of the Phase III study OASIS 3 providing additional efficacy and safety data over 52 weeks were presented at The Menopause Society (TMS) annual meeting in September 2024. Based on the positive results from the Phase III clinical development program, submissions for marketing authorizations for elinzanetant are ongoing in the US, EU and other markets around the world.

2024年8月。提供52周额外疗效和安全性数据的III期研究OASIS 3的详细结果在2024年9月的更年期学会（TMS）年度会议上公布。基于III期临床开发项目的积极结果，elinzanetant在美国、欧盟及其他全球市场的上市授权申请正在进行中。

In early 2025, positive topline results of OASIS 4 the first pivotal international Phase III study to assess the safety and efficacy of elinzanetant in moderate to severe VMS caused by adjuvant endocrine therapy were announced with details planned to be presented at upcoming scientific congresses..

2025 年初，公布了 OASIS 4 的阳性顶线结果，这是首个评估 elinzanetant 在辅助内分泌治疗引起的中度至重度 VMS 中的安全性和有效性的关键国际 III 期研究，详细信息计划在即将召开的科学大会上公布。

To view the complete program, please visit

要查看完整的程序，请访问

ESG congress website

ESG大会网站

。

About Elinzanetant

关于Elinzanetant

Elinzanetant is the first dual neurokinin-1 and 3 (NK-1, 3) receptor antagonist, in late-stage clinical development for the targeted treatment of moderate to severe VMS associated with menopause or caused by adjuvant endocrine therapy, administered orally once daily. Elinzanetant may address moderate to severe VMS by modulating a group of estrogen sensitive neurons in the hypothalamus region of the brain (the KNDy neurons) which, with the decrease of estrogen, become hypertrophic and lead to a hyperactivation of the thermoregulatory pathway, consequently disrupting body heat control mechanisms resulting in VMS.

Elinzanetant 是一种首创的双重神经激肽-1和3（NK-1，3）受体拮抗剂，目前处于晚期临床开发阶段，用于针对性治疗与更年期相关或由辅助内分泌治疗引起的中度至重度血管舒缩症状（VMS），每日一次口服给药。Elinzanetant 可能通过调节大脑下丘脑区域的一组雌激素敏感神经元（KNDy神经元）来解决中度至重度VMS，这些神经元在雌激素减少时变得肥大，导致体温调节通路的过度激活，从而扰乱身体的热量控制机制并引发VMS。

Based on key secondary endpoints of OASIS 1 and 2, elinzanetant may also decrease sleep disturbances associated with menopause..

基于OASIS 1和2的关键次要终点，elinzanetant也可能减少与更年期相关的睡眠障碍。

About Menopause

关于更年期

By 2030, the global population of women experiencing menopause is projected to increase to 1.2 billion, with 47 million women entering this phase each year. Menopause is a transitional phase in women’s lives, related to the progressive decline of ovarian function. It usually occurs in women during their 40s or early 50s.

到2030年，全球经历更年期的女性人口预计将增加到12亿，每年有4700万女性进入这一阶段。更年期是女性生命中的一个过渡阶段，与卵巢功能的逐渐衰退有关，通常发生在女性的40多岁或50岁出头。

The hormonal decline can lead to various symptoms which can substantially affect a woman’s health, quality of life, healthcare utilization and work productivity. The most frequently reported and disruptive symptoms during the menopausal transition are VMS, sleep disturbances and mood changes. Menopausal symptoms can also be the result of surgical or medical treatment.

激素水平的下降会导致各种症状，这些症状可能会严重影响女性的健康、生活质量、医疗资源利用和工作效率。在更年期过渡期间，最常报告且最具干扰性的症状是血管舒缩症状（VMS）、睡眠障碍和情绪变化。更年期症状也可能是手术或治疗的结果。

Addressing the symptoms is key to maintaining functional ability and quality of life which is highly relevant from both a healthcare and socio-economic perspective..

解决症状是保持功能能力和生活质量的关键，这从医疗保健和社会经济角度来看都非常重要。

About Women’s Healthcare at Bayer

关于拜耳的女性医疗保健

Women’s Health is in Bayer’s DNA. As a global leader in women’s healthcare Bayer has a long-standing commitment to delivering science for a better life by advancing a portfolio of innovative treatments. Bayer offers a wide range of effective short- and long-acting birth control methods as well as therapies for menopause management and gynecological diseases.

妇女健康深植于拜耳的DNA中。作为女性医疗保健领域的全球领导者，拜耳长期致力于通过推进一系列创新治疗方案来为美好生活提供科学支持。拜耳提供多种有效的短效和长效避孕方法，以及针对更年期管理和妇科疾病的治疗方案。

Bayer is also focusing on innovative options to address the unmet medical needs of women worldwide and to broadening treatment choices such as in menopause. Additionally, Bayer intends to provide 100 million women per year in low-and-middle income countries by 2030 with access to family planning by funding multi-stakeholder aid programs for capacity building and by ensuring the supply of affordable modern contraceptives.

拜耳还在专注于创新的选择，以解决全球女性未被满足的医疗需求，并拓宽如更年期等方面的治疗选择。此外，拜耳计划到2030年，通过资助多利益相关方的援助项目来加强能力建设，并确保提供价格合理的现代避孕药具，从而使低收入和中等收入国家的1亿女性每年获得计划生育服务。

This is part of the comprehensive sustainability measures and commitments from 2020 onwards and in line with the Sustainable Development Goals of the United Nations..

这是自2020年以来全面可持续发展措施和承诺的一部分，并与联合国的可持续发展目标相一致。

About Bayer

关于拜耳

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population.

拜耳是一家在医疗保健和营养等生命科学领域具有核心竞争力的全球性企业。秉承“人人健康，无饥饿”的使命，公司通过支持应对不断增长和老龄化的全球人口所带来的重大挑战，设计其产品和服务以帮助人类和地球繁荣发展。

Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2024, the Group employed around 93,000 people and had sales of 46.6 billion euros.

拜耳致力于通过其业务推动可持续发展并产生积极影响。同时，集团旨在通过创新和增长提高盈利能力并创造价值。拜耳品牌在全球范围内代表信任、可靠性和质量。在2024财年，集团拥有约93,000名员工，销售额达466亿欧元。

R&D expenses amounted to 6.2 billion euros. For more information, go to .

研发费用共计62亿欧元。欲了解更多信息，请访问。

www.bayer.com

。

Find more information at

更多信息请访问

https://pharma.bayer.com

关注我们的Facebook：

http://www.facebook.com/bayer

在LinkedIn上关注我们：

Bayer | Pharmaceuticals

拜耳 | 制药

Forward-Looking Statements

前瞻性声明

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here.

本发布可能包含基于拜耳管理层当前假设和预测的前瞻性声明。各种已知和未知的风险、不确定性和其他因素可能导致公司实际的未来结果、财务状况、发展或业绩与这里给出的估计值存在重大差异。

These factors include those discussed in Bayer’s public reports which are available on the Bayer website at .

这些因素包括拜耳公开报告中讨论的因素，这些报告可在拜耳网站上查阅。

www.bayer.com

. The company assumes no liability whatsoever to update these forward-looking statements or to conform

公司不承担更新这些前瞻性声明或使其符合的任何责任 whatsoever

them to future events or developments.

将它们应用于未来的事件或发展。

Contact

联系

Katja Wiggers

卡特娅·维格斯